Stromal cell rescue drug treatment in ALCL cells. (A) Heat map reporting the percentage of propidium iodide–positive (PI+) cells in ALCL cells cocultured with MS-5 cells or cultured alone and treated for 72 hours with crizotinib at the indicated concentrations (y-axis). (B) Heat map reporting the percentage of PI+ cells in ALCL cells cocultured with MS-5 cells or cultured alone and treated for 72 hours with ruxolitinib at the indicated concentrations (y-axis). (C) Heat map reporting the percentage of PI+ cells in ALCL cells cocultured with MS-5 cells or cultured alone and treated for 72 hours with navitoclax at the indicated concentrations (y-axis). (D) Bar plot indicating the percentage of PI+ cells in SUPM2 untreated (NT) or exposed to 20 nM of doxorubicin for 72 hours, in the presence or absence of MS-5. P values were estimated with 2-way analysis of variance (ANOVA) test using GraphPad software (∗P < .05; ∗∗P < .01; ∗∗∗P < .001; ∗∗∗∗P < .0001). (E) Bar plot indicating the percentage of PI+ cells in MAC1 NT or exposed to 40 nM of doxorubicin for 72 hours, in the presence or absence of MS-5. P values were estimated with 2-way ANOVA test using GraphPad software (∗P < .05; ∗∗P < .01; ∗∗∗P < .001; ∗∗∗∗P < .0001). (F) Bar plot indicating the percentage of PI+ cells in SUPM2 NT or exposed to 100 nM of crizotinib for 72 hours, in the presence or absence of F44. P values were estimated with 2-way ANOVA test using GraphPad software (∗P < .05; ∗∗P < .01; ∗∗∗P < .001; ∗∗∗∗P < .0001). (G) Bar plot indicating the percentage of PI+ cells in L82 NT or exposed to 150 nM of crizotinib for 72 hours, in the presence or absence of F44. P values were estimated with 2-way ANOVA test using GraphPad software (∗P < .05; ∗∗P < .01; ∗∗∗P < .001; ∗∗∗∗P < .0001). (H) Bar plot indicating the percentage of PI+ cells in SUPM2 NT or exposed to 100 nM of crizotinib for 72 hours, in the presence or absence of F89. P values were estimated with 2-way ANOVA test using GraphPad software (∗P < .05; ∗∗P < .01; ∗∗∗P < .001; ∗∗∗∗P < .0001). (I) Bar plot indicating the percentage of PI+ cells in DHL1 NT or exposed to 100 nM of crizotinib for 72 hours, in the presence or absence of F75. P values were estimated with 2-way ANOVA test using GraphPad software (∗P < .05; ∗∗P < .01; ∗∗∗P < .001; ∗∗∗∗P < .0001). (J) Bar plot indicating the percentage of PI+ cells in DHL1 NT or exposed to 100 nM of crizotinib for 72 hours, in the presence or absence of HS-5. P values were estimated with 2-way ANOVA test using GraphPad software (∗P < .05; ∗∗P < .01; ∗∗∗P < .001; ∗∗∗∗P < .0001). (K) Bar plot indicating the percentage of PI+ cells in IL-69 NT or exposed to 500 nM of crizotinib for 72 hours, in the presence or absence of HS-5. P values were estimated with 2-way ANOVA test using GraphPad software (∗P < .05; ∗∗P < .01; ∗∗∗P < .001; ∗∗∗∗P < .0001).
Figure 2.

Stromal cell rescue drug treatment in ALCL cells. (A) Heat map reporting the percentage of propidium iodide–positive (PI+) cells in ALCL cells cocultured with MS-5 cells or cultured alone and treated for 72 hours with crizotinib at the indicated concentrations (y-axis). (B) Heat map reporting the percentage of PI+ cells in ALCL cells cocultured with MS-5 cells or cultured alone and treated for 72 hours with ruxolitinib at the indicated concentrations (y-axis). (C) Heat map reporting the percentage of PI+ cells in ALCL cells cocultured with MS-5 cells or cultured alone and treated for 72 hours with navitoclax at the indicated concentrations (y-axis). (D) Bar plot indicating the percentage of PI+ cells in SUPM2 untreated (NT) or exposed to 20 nM of doxorubicin for 72 hours, in the presence or absence of MS-5. P values were estimated with 2-way analysis of variance (ANOVA) test using GraphPad software (∗P < .05; ∗∗P < .01; ∗∗∗P < .001; ∗∗∗∗P < .0001). (E) Bar plot indicating the percentage of PI+ cells in MAC1 NT or exposed to 40 nM of doxorubicin for 72 hours, in the presence or absence of MS-5. P values were estimated with 2-way ANOVA test using GraphPad software (∗P < .05; ∗∗P < .01; ∗∗∗P < .001; ∗∗∗∗P < .0001). (F) Bar plot indicating the percentage of PI+ cells in SUPM2 NT or exposed to 100 nM of crizotinib for 72 hours, in the presence or absence of F44. P values were estimated with 2-way ANOVA test using GraphPad software (∗P < .05; ∗∗P < .01; ∗∗∗P < .001; ∗∗∗∗P < .0001). (G) Bar plot indicating the percentage of PI+ cells in L82 NT or exposed to 150 nM of crizotinib for 72 hours, in the presence or absence of F44. P values were estimated with 2-way ANOVA test using GraphPad software (∗P < .05; ∗∗P < .01; ∗∗∗P < .001; ∗∗∗∗P < .0001). (H) Bar plot indicating the percentage of PI+ cells in SUPM2 NT or exposed to 100 nM of crizotinib for 72 hours, in the presence or absence of F89. P values were estimated with 2-way ANOVA test using GraphPad software (∗P < .05; ∗∗P < .01; ∗∗∗P < .001; ∗∗∗∗P < .0001). (I) Bar plot indicating the percentage of PI+ cells in DHL1 NT or exposed to 100 nM of crizotinib for 72 hours, in the presence or absence of F75. P values were estimated with 2-way ANOVA test using GraphPad software (∗P < .05; ∗∗P < .01; ∗∗∗P < .001; ∗∗∗∗P < .0001). (J) Bar plot indicating the percentage of PI+ cells in DHL1 NT or exposed to 100 nM of crizotinib for 72 hours, in the presence or absence of HS-5. P values were estimated with 2-way ANOVA test using GraphPad software (∗P < .05; ∗∗P < .01; ∗∗∗P < .001; ∗∗∗∗P < .0001). (K) Bar plot indicating the percentage of PI+ cells in IL-69 NT or exposed to 500 nM of crizotinib for 72 hours, in the presence or absence of HS-5. P values were estimated with 2-way ANOVA test using GraphPad software (∗P < .05; ∗∗P < .01; ∗∗∗P < .001; ∗∗∗∗P < .0001).

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal